A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2016
At a glance
- Drugs Ceritinib (Primary) ; Luminespib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 06 Jun 2016 Status changed from active, no longer recruiting to completed.
- 08 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
- 08 Jan 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.